Anne-Catherine Berner, new Grifols Chair

Barcelona, Spain, June 5, 2025 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines and innovative diagnostic solutions, has appointed Anne-Catherine Berner as the new non-executive Chair of Grifols after its 2025 Annual Shareholders’ Meeting. The newly appointed Chair succeeds outgoing Chairman, Thomas Glanzmann, who after two decades of dedication and commitment to the company did not stand for reelection.

Going forward, Grifols seeks to consolidate its strategy aimed at creating long-term sustainable value, with a firm commitment to research and innovation, as well as progress towards self-sufficiency in plasma.

Anne-Catherine Berner addressed Grifols shareholders: "It is an honor to be part of such an exceptional company, which for more than a century has improved the lives of millions of people. The values that have brought us this far are the cornerstones of our success and will continue to guide our path going forward. As Chair, I will work to maintain the high standards of quality, rigor, transparency and governance that characterize the company, and will look out for the best interests of our patients and donors with an eye on the long term."

Raimon Grifols, Grifols Vice-Chairman and Board member, took the opportunity to welcome the new Chair and thank the departing Chairman for his years of service: "Since joining the Board of Directors as an independent director in 2024, Anne has demonstrated her ability and vision to lead Grifols. We are convinced that her experience, judgment and leadership will make a decisive contribution to the company's success in this new phase. We also say a very special thank you to Thomas for 20 years of outstanding commitment to Grifols, always acting in the best interests of Grifols and its stakeholders."

Grifols' shareholders supported all the items on the agenda put to the vote at the 2025 General Shareholders' Meeting, held today at Grifols' headquarters in Sant Cugat del Vallès. 602 shareholders, holders of 297,122,195 Class A shares, representing 69.72% of the company's share capital with voting rights, were represented at the meeting. The broad support received at the meeting reflects the confidence of the shareholders in Grifols' fundamental pillars and the company's strategic direction.

During the meeting, the shareholders supported the reelection of Víctor Grifols Deu as a member of the Board of Directors. His continuity on the company's governing body has been endorsed by his in-depth knowledge of the business and his key role in the development and consolidation of the company's main strategic projects in recent years, while guaranteeing the continuity of a vision aligned with Grifols' long-term objectives. In addition, the shareholders also approved the ratification of Pascal Ravery as an independent director. Paul S. Herendeen has been designated as a proprietary director by shareholders Flat Footed, Mason Capital and Sachem Head.

Other noteworthy proposals included the shareholders' endorsement of the 2024 financial statements, in which the company exceeded forecasts with revenues reaching €7,212 million, an increase of 10.3% at constant exchange rates, adjusted EBITDA of €1,779 million, with an operating margin of 24.7%, and net profit of €157 million. The company also reported that all the innovation milestones planned for 2024 have been reached, including the submission of fibrinogen approval applications both in the European Union and the United States.

Shareholders also endorsed the company's director compensation policy and stock incentive plan for 2025, as well as the reduction of the number of members of the Board of Directors to 12.

For more information: Grifols General Shareholders' Meeting and Grifols Annual Integrated and Sustainability Report 2024.